ArticleBMC cardiovascular disorders2025
Artificial intelligence-enhanced three-dimensional echocardiography reveals left atrial-ventricular coupling index as a novel prognostic marker in coronary artery disease.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Left Atrioventricular Coupling Index: A Comprehensive Review of the Literature.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe Left Atrial-Ventricular Coupling Index (LACI), which quantifies the volumetric interaction between the left atrium and ventricle, has emerged as a promising prognostic marker for cardiovascular events.
methodsWe applied three-dimensional echocardiography (3DE) and AI quantitative software to automatically obtain the new echocardiographic parameter LACI in 1084 coronary artery disease (CAD) patients at the Fourth Affiliated Hospital of China Medical University. LACI was defined as the ratio between the left atrial end-diastolic volume and the left ventricular end-diastolic volume. The primary endpoints were major adverse cardiovascular events (MACE), including unstable angina, myocardial reinfarction, heart failure (HF) and death.
resultsOver a median follow-up of 13 months, 216 MACE were recorded. LACI was significantly higher in patients with MACE than in those without (0.22 [IQR 0.17–0.28] vs. 0.20 [IQR 0.15–0.25], p < 0.001). ROC analysis indicated that LACI demonstrated higher predictive accuracy for MACE than traditional echocardiography parameters. Multivariable Cox regression analysis revealed that LACI was significantly correlated with MACE (HR: 1.68, 95% CI [1.25–2.27], p < 0.001), especially in patients with severe lesion subgroups according to the Gensini scores (HR 1.33, 95% CI [1.17–1.52], p < 0.002) and male (HR: 1.37, 95% CI [1.20–1.56], p < 0.002). Furthermore, LACI assessment enabled further risk stratification in high-risk patients with severe lesion (p < 0.001 on log-rank testing). Consistently, category-free NRI and IDI confirmed the improvement by LACI to stratify MACE risk in severe lesion patients (p < 0.05).
conclusionOur findings demonstrated that AI-enhanced 3DE-derived LACI provided incremental prognostic value beyond conventional echocardiographic parameters in assessing the prognosis among CAD patients, especially in severe coronary lesion subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.